Acusphere - Worst Pharma Stocks of 2007

Company: Acusphere
Starting stock price: $2.51
Ending stock price: $0.65
Percent Change: -74.10%

Details: Acusphere is focused on developing drugs using its microsphere technology. Its lead candidate is Imagify, an injectable for use during ultrasound or echocardiograms; it's designed to show perfusion, an indicator of heart disease. Its second Phase III trials of the compound were announced in May 2007 and the company is working with the FDA on a New Drug Application, which would require its manufacturing facility in Massachusetts to be certified. It expects to submit the NDA early this year.

Acusphere - Worst Pharma Stocks of 2007

Suggested Articles

How long can one infusion of Gilead CAR-T drug Yescarta continue to help patients with refractory large B-cell lymphoma? Pretty long, Gilead showed.

AbbVie and Roche have been fielding their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan could keep chro

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.